Exploring Protara Therapeutics, Inc. (TARA) Investor Profile: Who’s Buying and Why?

Are you keeping tabs on Protara Therapeutics, Inc. (TARA) and wondering who's investing and what's driving their decisions? As of December 31, 2024, institutional investors held a significant stake, with a total of 29,967,599 shares. Major players like Ra Capital Management, L.p. held 3,400,000 shares, Janus Henderson Group Plc with 2,271,832 shares, and Adage Capital Partners Gp, L.l.c. with 2,250,000 shares are among the top stakeholders. With a recent stock price of $3.85 on April 21, 2025, and analysts predicting a potential upside of over 428% from its current trading price, what makes Protara Therapeutics an attractive investment for these major players? Let's delve into the investor profile of Protara Therapeutics to uncover the motivations behind their investments.

Protara Therapeutics, Inc. (TARA) Who Invests in Protara Therapeutics, Inc. (TARA) and Why?

Understanding the investor profile of Protara Therapeutics, Inc. (TARA) involves examining the various types of investors, their motivations, and the strategies they employ. This provides insights into the market's perception of the company and its future prospects. Here’s a breakdown to give you a clearer picture.

Key Investor Types

Protara Therapeutics, Inc. (TARA) attracts a mix of retail and institutional investors, each with different investment horizons and risk tolerances.

• Retail Investors: These are individual investors who buy and sell shares for their own accounts. They may be drawn to Protara Therapeutics, Inc. (TARA) due to its potential for growth in the biotechnology sector.
• Institutional Investors: These include entities such as mutual funds, hedge funds, pension funds, and insurance companies. Institutional investors often have larger stakes and can significantly influence the stock price.

Investment Motivations

Several factors might attract investors to Protara Therapeutics, Inc. (TARA):

• Growth Prospects: Biotechnology companies like Protara Therapeutics, Inc. (TARA) are often seen as growth stocks. Investors are attracted by the potential for high returns if the company successfully develops and commercializes its products.
• Market Position: The company's position in the competitive landscape of its specific therapeutic areas also plays a crucial role. A unique or leading position can be a strong motivator for investment.

Investment Strategies

The strategies employed by investors in Protara Therapeutics, Inc. (TARA) can vary widely:

• Long-Term Holding: Some investors may adopt a long-term holding strategy, banking on the company's future success and potential for significant capital appreciation over several years.
• Short-Term Trading: Other investors might engage in short-term trading, seeking to profit from the stock's price volatility. This strategy is more speculative and involves frequent buying and selling.
• Value Investing: Value investors look for companies that they believe are undervalued by the market. They may see Protara Therapeutics, Inc. (TARA) as a value play if they believe the company's intrinsic value is higher than its current stock price.

For further insights into the financial health of Protara Therapeutics, Inc. (TARA), you might find this resource helpful: Breaking Down Protara Therapeutics, Inc. (TARA) Financial Health: Key Insights for Investors

Protara Therapeutics, Inc. (TARA) Institutional Ownership and Major Shareholders of Protara Therapeutics, Inc. (TARA)

Protara Therapeutics, Inc. (TARA) has a notable institutional ownership structure, with a significant percentage of its shares held by institutional investors. As of April 2025, 82 institutional owners and shareholders have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC), holding a total of 29,967,599 shares.

Major shareholders of Protara Therapeutics, Inc. can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held) more than 5% of the company and intends (or intended) to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%.

Here's a list of the top institutional investors in Protara Therapeutics, Inc. (TARA) based on recent filings:

• RA Capital Management, L.P.: Holding 3,400,000 shares
• Janus Henderson Group Plc: Holding 2,271,832 shares
• Adage Capital Partners Gp, L.L.C.: Holding 2,250,000 shares
• Toronto Dominion Bank: Holding 2,088,937 shares
• Opaleye Management Inc.: Holding 1,825,000 shares
• Blackstone Group Inc: Holding 1,680,000 shares
• Velan Capital Investment Management LP: Holding 1,579,000 shares
• Sio Capital Management, LLC: Holding 1,437,500 shares
• Integral Health Asset Management, LLC: Holding 1,400,000 shares
• Vanguard Group Inc: Holding 1,359,509 shares

These major institutions can significantly influence Protara Therapeutics, Inc.'s (TARA) stock performance. For instance, analysts predict major upside for Protara Therapeutics. Protara Therapeutics (NASDAQ:TARA) has received unanimous 'Buy' ratings from five analysts, with a consensus 12-month price target of $22.50. This represents a potential upside of over 428% from its current trading price of $4.26.

The share price as of April 17, 2025 is $3.90 / share. Previously, on April 19, 2024, the share price was $2.64 / share. This represents an increase of 47.73% over that period.

Changes in institutional ownership can offer insights into the sentiment surrounding Protara Therapeutics, Inc.. Recent data indicates a dynamic landscape:

• Increase in Institutional Ownership: Protara Therapeutics has seen a 172% increase in institutional ownership over the past three months, with 74 funds now holding positions.
• Fund Sentiment: The Fund Sentiment Score identifies stocks being heavily bought by funds, utilizing a multi-factor quantitative model.

Institutional investors play a crucial role in the stock price and strategy of Protara Therapeutics, Inc.. Their actions can drive price movements and reflect confidence in the company's prospects. For example, rising earnings estimates and subsequent rating upgrades can attract institutional investors, leading to increased buying activity and upward price movement.

The influence of institutional investors is also evident in their use of earnings and earnings estimates to determine the fair value of Protara Therapeutics, Inc.'s shares. An increase or decrease in earnings estimates in their valuation models can result in higher or lower fair value for a stock, prompting institutional investors to buy or sell, which subsequently affects the stock price.

Recent news highlights the potential impact of these investors:

• Analyst Optimism: Analysts remain bullish on Protara Therapeutics, Inc., citing potential growth driven by its clinical-stage therapies, despite recent market volatility.
• Earnings Outlook: A Zacks Rank #2 (Buy) upgrade reflects an upward trend in earnings estimates, potentially leading to a favorable impact on its stock price. For the fiscal year ending December 2025, this kidney and vascular disease drug developer is expected to earn -$1.74 per share, which is a change of 19.8% from the year-ago reported number. Over the past three months, the Zacks Consensus Estimate for the company has increased 40.6%.

For more insights into Protara Therapeutics, Inc.'s financial health, consider exploring this resource: Breaking Down Protara Therapeutics, Inc. (TARA) Financial Health: Key Insights for Investors

Protara Therapeutics, Inc. (TARA) Key Investors and Their Impact on [Company Name]

Understanding the investor profile of Protara Therapeutics, Inc. (TARA) provides valuable insights into the company's stability, growth potential, and strategic direction. Examining notable investors, their influence, and recent moves can offer a clearer picture of market sentiment and potential future performance. For more background information, you can explore Protara Therapeutics, Inc. (TARA): History, Ownership, Mission, How It Works & Makes Money.

While specific, real-time major investor details and their direct impact on Protara Therapeutics, Inc. (TARA) are subject to constant change and often proprietary, we can discuss the types of investors and their potential influence based on general market knowledge and publicly available information. Institutional investors, such as hedge funds, mutual funds, and pension funds, often hold significant stakes in publicly traded companies like Protara Therapeutics, Inc. (TARA). Their investment decisions can drive stock price movements and influence corporate strategy.

Here's how different types of investors can impact Protara Therapeutics, Inc. (TARA):

• Institutional Investors:
• Hold substantial shares, leading to significant influence on stock price and company direction.
• Actively engage with company management regarding performance and strategy.
• Retail Investors:
• Individual investors whose collective actions can impact stock volatility, especially with increased social media influence.
• Their sentiment can drive short-term price fluctuations.
• Activist Investors:
• Acquire large stakes to push for specific changes (e.g., strategic shifts, management changes).
• Can significantly alter company policy and direction through public campaigns or private negotiations.

To illustrate the potential impact of investor actions, consider the following hypothetical scenarios:

Keeping track of significant investor moves, such as large stake acquisitions or divestitures, and understanding the motivations behind these actions, can provide valuable insights into the potential future trajectory of Protara Therapeutics, Inc. (TARA). Always refer to reliable financial news sources and regulatory filings for the most up-to-date and accurate information.

Protara Therapeutics, Inc. (TARA) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions to Protara Therapeutics, Inc. (TARA) is crucial for assessing the company's current standing and future prospects. Analyzing major shareholder activity, recent market behavior, and analyst perspectives provides a comprehensive view of the factors influencing Protara Therapeutics, Inc. (TARA).

Protara Therapeutics, Inc. (TARA) is a biopharmaceutical company focused on the development of transformative therapies for treating cancer and rare diseases. Their approach involves innovative technologies and a commitment to addressing unmet medical needs. More information about their mission, vision, and core values can be found at: Mission Statement, Vision, & Core Values of Protara Therapeutics, Inc. (TARA).

Investor Sentiment:

Current investor sentiment toward Protara Therapeutics, Inc. (TARA) can be gauged by examining the behavior of its major shareholders. While specific sentiments (positive, neutral, or negative) can fluctuate, significant changes in holdings by institutional investors often signal shifts in confidence. For example, increased buying activity may indicate a positive outlook based on clinical trial results or market potential, whereas increased selling could reflect concerns about regulatory hurdles or financial performance. As of the most recent data, key institutional investors and their positions include:

• Vanguard Group: Holding 1,676,595 shares
• BlackRock Fund Advisors: Holding 1,217,301 shares
• State Street Corporation: Holding 447,853 shares

These major holders reflect a mix of investment strategies, from index tracking to active management, all influencing the overall market perception of Protara Therapeutics, Inc. (TARA).

Recent Market Reactions:

The stock market's response to changes in ownership or large investor moves provides valuable insights. Significant investments or divestments by major shareholders often trigger noticeable stock price fluctuations. Positive clinical trial outcomes, regulatory approvals, or strategic partnerships tend to drive positive market reactions, while setbacks or negative news can lead to declines. Monitoring these reactions helps in understanding the market's immediate assessment of Protara Therapeutics, Inc. (TARA)'s prospects.

As an example, let's look at the recent stock performance and news events related to Protara Therapeutics, Inc. (TARA):

• On March 25, 2024, Protara Therapeutics, Inc. (TARA) announced positive initial data from its Phase 1 study of TARA-002 in adults with non-muscle invasive bladder cancer (NMIBC). This news led to a surge in investor interest and a corresponding increase in the stock price.
• Conversely, on February 14, 2024, the company announced its financial results for the fourth quarter of 2023, reporting a net loss. While the details of the loss were factored into the company's long-term strategy, the immediate market reaction was a slight dip in the stock price as investors digested the financial data.

Analyst Perspectives:

Analyst perspectives offer informed opinions on the potential impact of key investors on Protara Therapeutics, Inc. (TARA)'s future. Analysts consider various factors, including the company's financial health, pipeline progress, and market opportunities, to provide recommendations and price targets. These insights help investors make informed decisions by offering a professional assessment of the company's value and growth prospects. Here’s a snapshot of what analysts are saying:

As of April 2025, analyst ratings and price targets for Protara Therapeutics, Inc. (TARA) vary, reflecting different perspectives on the company's potential:

• An analyst from HC Wainwright & Co. reiterated a 'Buy' rating on Protara Therapeutics, Inc. (TARA) with a price target of $32.00.
• Similarly, analysts at Brookline Capital Management initiated coverage on Protara Therapeutics, Inc. (TARA) with a 'Buy' rating and a price target of $31.00.

These ratings suggest a generally positive outlook, driven by expectations of continued progress in clinical trials and potential market approvals.

Ownership Structure and Recent Changes:

Analyzing the ownership structure of Protara Therapeutics, Inc. (TARA) provides insights into the distribution of shares among different types of investors. Shifts in ownership, particularly among institutional investors, can indicate changing sentiment and expectations regarding the company's performance. The following table summarizes the ownership composition of Protara Therapeutics, Inc. (TARA):

Understanding these ownership dynamics is essential for gauging the stability and potential volatility of Protara Therapeutics, Inc. (TARA)'s stock.